The R-Pharm group of companies received a permanent registration certificate from the Russian Ministry of Health for its own drug remdesivir, intended for the treatment of coronavirus infection. The registration certificate valid until 2028 was obtained in accordance with the rules of registration and examination of the EAEU.
The drug remdesivir is able to be incorporated into nascent RNA chains by the RNA-dependent RNA polymerase of the SARS-CoV-2 virus, which leads to delayed chain termination during viral RNA replication. It is used in treatment regimens for mild, moderate, severe and extremely severe coronavirus infections and is included in the guidelines of the Russian Ministry of Health for the prevention, diagnosis and treatment of COVID-19.
